Navigation Links
Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
Date:5/18/2011

PITTSBURGH, May 18, 2011 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com), manufacturers of noninvasive medical diagnostic equipment used worldwide for neuro-physiologic, neuro-otologic, vestibular and neurological testing, said today that it has released version 6.10 of its VEST™ control and analysis software.

Clinical specialists use NKI's I-Portal® devices and VEST software to conduct vestibular, oculomotor and optokinetic tests to detect and measure balance- and dizziness-related pathologies, as well as for research and validation of these tests to detect concussions or mild Traumatic Brain Injury (mTBI). 

"We take pride in being the innovative leader in our markets," said Vince Kytka, director, operations and marketing.  "With our updated software, we are enabling our clinical users around the world to do more for their patients."

The most significant upgrade is the enhancement of the Dynamic Unilateral Centrifugation with SVV test. It was modified so that the user can collect multiple (two to four) SVV data points during each eccentric position.  This allows for separate calculations of mean and standard deviation for each right, center and left patient positions. The results have also been added to the analysis and report feature in VEST.

Version 6.10 also includes improved user interfaces, including:

  • The optokinetic test analysis table is now sorted by OKN velocity for easier viewing.
  • The analysis simulation (animated playback of eye movement) page has been reorganized and relabeled for easier use during data review.

In addition, 10 bugs identified by Neuro Kinetics and its users over the past year have been fixed.  

Some of the fixes include:

  • The VNG eye video file saving error.
  • The upbeat and downbeat nystagmus labeling in the Gaze Horizontal, Gaze Vertical and Spontaneous Nystagmus Tests.
  • The SHA Test analysis was modified to delete full cycles instead of partial cycles.  

NKI has established a beta testing program with Bloomsburg and Gallaudet Universities and, as a result, 6.10 has gone through the most rigorous and extensive testing of any software version the company has introduced.  

NKI's first I-Portal® NOTC system with VEST 6.10 shipped last week and all warranty and software- subscription customers received instructions for the upgrade and are downloading it now.

For more information about VEST or any other NKI product or service, please contact Neuro Kinetics at +1.412.963.6649 or via e-mail to sales@neuro-kinetics.com.

ABOUT NEURO KINETICS, INC.

Neuro Kinetics, Inc. (NKI) is the world leader in eye-tracking technology and non-invasive neuro-otologic diagnostic testing.  Central to its product mix and technological advances is the premise that the eye is the portal to the brain.  Research has shown the detection of abnormal eye reflexes can indicate the presence of more than 200 diseases and medical conditions.

For more than 25 years, NKI has supplied multi-modal neuro-otologic diagnostic tools to audiologists, ENT's, neuro-otologists, neuro-ophthalmologists and neurologists around the globe.  The company's patented products include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services.

MEDIA CONTACT:

John Buckman
Buckman Communications, for Neuro Kinetics, Inc.
+ 1 412-381-2900 or jbuckman@buckman.biz


'/>"/>
SOURCE Neuro Kinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurologix Announces First Quarter 2011 Financial Results
2. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
3. NeurogesX to Present at 10th Annual JMP Securities Research Conference
4. Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference
5. NeurogesX Reports First Quarter 2011 Results
6. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
7. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
8. Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX®
9. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
10. Reportlinker Adds Neuropathy Therapy Area Pipeline Report
11. Reportlinker Adds Europe Neurology Devices Market Outlook to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... report published by Allied Market Research titled, "World ... and Forecasts, 2014-2020", estimates the world synthetic biology ... synthesis and sequencing technology segment would continue to ... software tools segment, collectively, held around half of ...
(Date:2/5/2016)... N.C. , Feb. 5, 2016  Despite the ... been slower than other industries to embrace Big Data ... with utilization. On the medical side, organizations have begun ... everything from clinical trials to adherence. ... from benchmarking firm Best Practices, LLC, Big Data has ...
(Date:2/5/2016)... 5, 2016  Syneron Medical Ltd. (NASDAQ: ... announced today that William Griffing , Chief ... scheduled to participate in the Leerink Partners 5 ... 11, 2016 in New York City ... to meet with the Mr. Griffing and will ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... ... 08, 2016 , ... The schedule is now online for the ... Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues ... and causes of chronic illness in children. , Very recent articles have cited 1 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):